138 / 1631
0
2 0
4 0
6 0
8 0
0
2 0
4 0
6 0
8 0
1 0 0
C o n tro l
DT
R T +
C D 4 0 m A b
R T +
C D 4 0 m A b + D T
*
T im e a f te r tu m o r
im p la n ta t io n (d a y s )
P e rc e n t s u rv iv al
CD40 mAb
RT +
CD40 mAb + DT
RT +
0
20
40
60
80
100
Incidence of lymph node
metastasis (% of treated cohort)
- DT
+ DT
CD11c depletion
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
C o n tro l
R T +
C D 4 0 m A b
DT
R T +
C D 4 0 m A b + D T
*
T im e a f te r tu m o r
im p la n ta t io n (d a y s )
P ercen t su rvival
Dendritic cell depletion abrogates the therapeutic effect of RT
and anti-CD40 combinations
0
2 0
4 0
6 0
0
2 0
4 0
6 0
8 0
1 0 0
C o n tro l
R T + T L R -7 a g o n is t
R T + T L R -7 a g o n is t + D T
R T + T L R -7 a g o n is t +
C D 2 0m A b
n / s
T im e a f te r tu m o r
im p la n ta tio n (d a y s )
Percent survival
S. J. Dovedi, G.L. Bhalla, S.A. Beers, E. J. Cheadle, L Mu, M.J. Glennie, T.M. Illidge, J. Honeychurch.
(Cancer Immunol Res. 2016 Jul;4(7):621-30)